U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116473) titled 'To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)' on Aug. 07.
Brief Summary: The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Amyloidosis in Transthyretin (TTR)
Amyloidosis, Familial
Amyloid Cardiomyopathy
Amyloid Cardiomyopathy, Transthyretin-Related
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Heart Disease
Cardiomyopa...